Imagion Biosystems has released Appendix 3Z Final Director’s Interest Notice. Read the Final Director’s Interest Notice.
Imagion MagSense Breast Cancer Program Phase 2 Clinical Trial Update
Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging